Table 1.
Cytotoxicity activity of different vaccine carriers.
| Vaccine type | % Haemolytic activitya |
|---|---|
| LLO | 100 ± 03 |
| bBM-DM/LLObound | 80 ± 02 |
| BM-DM-IFN /LLObound | 80 ± 05 |
| BM-DM/LLOint | 51 ± 02 |
| BM-DM-IFN/LLOint | 50 ± 04 |
| BM-DM/LM | 2 ± 005 |
| BM-DM-IFN/LM | 3 ± 003 |
| ENDO/LLO | 1 ± 005 |
| ENDO-IFN/LLO | 2 ± 002 |
SRBC haemolytic analysis after treatment with 300 µg/ml of recombinant LLO or the different vaccine types and performed as in Materials and Methods. Results are expressed as percentage of haemolytic activity compared with 100% haemolysis ± SD. Results are the mean ± SD of triplicate samples (p < 0.05).
The different vaccine types to be tested for their haemolytic activity were the following: BM-DM/ LLObound corresponds with untreated BM-DM incubated for 15 min with 300 µg/ml of LLO at 4ºC, BM-DM-IFN/LLObound corresponds with IFN-γ treated BM-DM incubated for 15 min with 300 µg/ml of LLO at 4ºC, BM-DM/LLOint corresponds with untreated BM-DM incubated for 15 min with 300 µg/ml of LLO at 37ºC, BM-DM-IFN/LLOint corresponds with IFN-γ treated BM-DM incubated for 15 min with 300 µg/ ml of LLO at 37ºC, BM-DM/LM corresponds with untreated BM-DM infected with LM, BM-DM-IFN/LM corresponds with IFN-γ treated BM-DM infected with LM, ENDO/LLO corresponds to 30 µg of isolated endosomes from untreated BM-DM loaded with LLO and ENDO-IFN/LLO corresponds to 30 µg of isolated endosomes from IFN-γ treated BM-DM loaded with LLO.